CDK4/6抑制剂TCK-276在活动性类风湿关节炎患者中的双盲、安慰剂对照、随机多剂量1b期试验
这项多中心、随机、安慰剂对照、剂量递增、双盲、1b期多剂量研究纳入32例活动性RA患者,分4个队列(每队列8例,6例活性药+2例安慰剂),口服TCK-276或安慰剂每日一次共7天,剂量为10、25、75、175 mg/日。结果显示TCK-276(≤175 mg)耐受良好,无临床意义的安全性信号,≥25 mg/日初步显示疗效,作者认为需进一步研究。
要点
- TCK-276(≤175 mg)在活动性RA患者中耐受良好,无临床意义的安全性信号。
- 第7天DAS28-CRP EULAR良好或中度应答率在25、75、175 mg/日组分别为40%、80%、66.7%,安慰剂组为12.5%。
- 第7天ACR20应答率在25、75、175 mg/日组分别为33.3%、60%、50%,安慰剂组为0%。
核心结论
- TCK-276(≤175 mg)在活动性RA患者中耐受良好,无临床意义的安全性信号,≥25 mg/日初步显示疗效,这些数据支持进一步研究TCK-276治疗活动性RA。
研究设计与样本
- 多中心、随机、安慰剂对照、剂量递增、双盲、1b期多剂量研究,纳入32例活动性RA患者,分4个队列,每队列8例(6例活性药+2例匹配安慰剂),口服TCK-276或匹配安慰剂每日一次共7天。
- TCK-276剂量为10、25、75、175 mg/日。
主要发现
- 无死亡、严重不良事件、值得注意的临床意义实验室发现(包括血液学变化)、临床意义生命体征变化或临床意义心电图或心脏遥测变化。
- TCK-276快速吸收,半衰期约为6至12小时,未见明显蓄积,TCK-276暴露增加呈剂量比例。
- 第7天DAS28-CRP应答(EULAR良好或中度应答)在25、75、175 mg/日TCK-276组分别为40%、80%、66.7%,安慰剂组为12.5%。
- 第7天ACR20应答在25、75、175 mg/日TCK-276组分别为33.3%、60%、50%,安慰剂组为0%。
关键数值与推荐
- 第7天DAS28-CRP EULAR良好或中度应答率:25 mg/日组40%、75 mg/日组80%、175 mg/日组66.7%,安慰剂组12.5%。
- 第7天ACR20应答率:25 mg/日组33.3%、75 mg/日组60%、175 mg/日组50%,安慰剂组0%。
- TCK-276半衰期约为6至12小时,未见明显蓄积,暴露增加呈剂量比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出这些数据需进一步研究TCK-276用于活动性RA的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and efficacy (as an exploratory endpoint) of TCK-276, a novel CDK4/6 inhibitor, after multiple oral doses for 7 days in patients with active RA. METHODS: This multicentre, randomized, placebo-controlled, dose-ascending, double-blind, phase 1b, multiple-dose study included 32 patients with active RA in four cohorts of 8 patients (6 active and 2 matching placebo), each receiving an oral dose of TCK-276 or matching placebo for 7 days (once daily). The doses of TCK-276 were 10, 25, 75 and 175 mg/day. Safety and pharmacokinetic endpoints, and exploratory disease activity parameters for RA were assessed. RESULTS: There were no deaths, serious adverse events, notable clinically meaningful laboratory findings (including haematological changes), clinically meaningful vital sign changes or clinically meaningful ECG or cardiac telemetry changes. TCK-276 was rapidly absorbed and the half-life time ranged approximately from 6 to 12 h. No obvious accumulation was observed, and the increase in TCK-276 exposure was dose proportional. At day 7, DAS28-CRP responses (EULAR good or moderate responses) were observed in 40%, 80% and 66.7% at 25, 75 and 175 mg/day TCK-276, respectively, vs 12.5% in placebo; ACR20 responses were 33.3%, 60% and 50%, respectively, vs none in placebo. CONCLUSION: TCK-276 (≤175 mg) was well tolerated with no clinically meaningful safety signals in patients with active RA. Together with the preliminary efficacy (≥25 mg/day), these data warrant further study of TCK-276 for the treatment of active RA. TRIAL REGISTRATION: ClinicalTrails.gov, NCT05437419.
引用
- Tasaki D, Tsuruda K, Sun S, et al. A double-blind, placebo-controlled, randomized multiple dose phase 1b trial of a CDK4/6 inhibitor, TCK-276, in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 39002122. doi:10.1093/rheumatology/keae357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。